Peptron Inc
KOSDAQ:087010
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
P
|
Peptron Inc
KOSDAQ:087010
|
KR |
|
Sino Biopharmaceutical Ltd
HKEX:1177
|
HK |
|
Hangzhou Weiguang Electronic Co Ltd
SZSE:002801
|
CN |
|
Daewoo Shipbuilding & Marine Engineering Co Ltd
KRX:042660
|
KR |
|
H
|
Hansol Paper Co Ltd
KRX:213500
|
KR |
|
S
|
Structural Monitoring Systems PLC
ASX:SMN
|
AU |
|
UET United Electronic Technology AG
XETRA:CFC
|
DE |
|
Aksa Enerji Uretim AS
IST:AKSEN.E
|
TR |
|
N
|
NZ Automotive Investments Ltd
NZX:NZA
|
NZ |
|
Bechtle AG
XETRA:BC8
|
DE |
|
Port Inc
TSE:7047
|
JP |
|
Fu Shou Yuan International Group Ltd
OTC:FSHUF
|
CN |
|
R
|
Redington (India) Ltd
NSE:REDINGTON
|
IN |
|
H
|
Hang Lung Group Ltd
HKEX:10
|
HK |
|
Go Fashion (India) Ltd
NSE:GOCOLORS
|
IN |
|
Core Lithium Ltd
ASX:CXO
|
AU |
|
C
|
China Tobacco International HK Co Ltd
HKEX:6055
|
HK |
|
A
|
Aib Group PLC
ISEQ:A5G
|
IE |
|
Gofore Oyj
LSE:0CXS
|
FI |
|
America Movil SAB de CV
NYSE:AMX
|
MX |
|
A
|
Altea Green Power SpA
MIL:AGP
|
IT |
|
Brookfield Corp
NYSE:BN
|
CA |
|
Golden Entertainment Inc
NASDAQ:GDEN
|
US |
Peptron Inc
Peptron Inc., a biotechnology firm based in South Korea, is weaving a narrative of innovation that marries cutting-edge research with real-world applications. Founded in 1997, the company has carved a niche in the realm of peptide-based pharmaceuticals, focusing on the formulation and delivery of these potent compounds for chronic diseases. Central to its story is the SmartDepot™ technology, a proprietary drug delivery system that ensures precise, sustained release of medication. This technology not only enhances patient compliance by reducing the frequency of dosing but also maximizes therapeutic efficacy, positioning Peptron as a trailblazer in improving patient care.
At the heart of Peptron's business model is its ability to capitalize on its advanced drug delivery systems by collaborating with global pharmaceutical giants and seeking strategic partnerships. With a robust pipeline, including promising treatments for Parkinson's disease and various endocrine disorders, Peptron generates revenue through licensing deals, co-development agreements, and the eventual commercialization of its therapeutics. By balancing research innovation with savvy business collaborations, Peptron is not just navigating the competitive biotech landscape; it is rewriting the narrative on harnessing technology for transformative healthcare solutions.
Peptron Inc., a biotechnology firm based in South Korea, is weaving a narrative of innovation that marries cutting-edge research with real-world applications. Founded in 1997, the company has carved a niche in the realm of peptide-based pharmaceuticals, focusing on the formulation and delivery of these potent compounds for chronic diseases. Central to its story is the SmartDepot™ technology, a proprietary drug delivery system that ensures precise, sustained release of medication. This technology not only enhances patient compliance by reducing the frequency of dosing but also maximizes therapeutic efficacy, positioning Peptron as a trailblazer in improving patient care.
At the heart of Peptron's business model is its ability to capitalize on its advanced drug delivery systems by collaborating with global pharmaceutical giants and seeking strategic partnerships. With a robust pipeline, including promising treatments for Parkinson's disease and various endocrine disorders, Peptron generates revenue through licensing deals, co-development agreements, and the eventual commercialization of its therapeutics. By balancing research innovation with savvy business collaborations, Peptron is not just navigating the competitive biotech landscape; it is rewriting the narrative on harnessing technology for transformative healthcare solutions.
